JPRN-UMIN000000714已完成2 期
A feasibility test on a postoperative Docetaxel plus TS-1 therapy for the patients with stage IIIA or stage IIIB gastric cancer (OGSG-0604) - A feasibility test on a postoperative Docetaxel plus TS-1 therapy for the patients with stage IIIA or stage IIIB gastric cancer (OGSG-0604)
OGSG0 个研究点目标入组 53 人开始时间: 2007年5月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 53
研究概览
简要总结
The OS rate at 3 years was 78.4 % [95 % confidence interval (CI), 67.9-90.6 %] and the DFS rate at 3 years was 66.2 % (95 % CI, 54.4-80.7 %).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. with double cancer and/or multiple cancer 2. patients who cannot take TS-1 3. patients who need flucitosine, fenitoin or warfarin 4. with allergic history against medicines 5. with severe allergic response against polysolbate 80 6. without any disorder on the chest X-ray or CT, or interstitial pneumonitis or pulmonary fibrosis 7. with other severe diseases (intestinal paralysis, intestinal obstruction, uncontrolled DM, cardiac failure, or liver dysfunction) 8. watery diarrhea 9. pregnant and/or nursing women 10. men who need their children in future 11. liver cirrhosis or active hepatitis 12. cavity fluid which should be taken out 13. doctors' stop not to register to the study
研究者
相似试验
已完成
不适用
A phase ll study to show the feasibility of six months continuous administration of Docetaxel+TS-1 for patients with Stage lllA/lllB gastric cancer after surgical resection (OGSG 1002)gastric cancerJPRN-UMIN000004440Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)62
进行中（未招募）
1 期
A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer. - PROSTY trialMetastatic Hormone Refractory Prostate Cancer.MedDRA version: 8.1Level: PTClassification code 10060862Term: Prostate cancerEUCTR2004-004295-37-IEAll-Ireland Cooperative Oncology Research Group360
已完成
2 期
Study of Docetaxel followed by FEC as primary systemic chemotherapy for operable breast cancer (JBCRG-03)Operable breast cancerJPRN-C000000291Japan Breast Cancer Research Group (JBCRG)137
进行中（未招募）
不适用
A phase III trial comparing docetaxel every third week to biweekly docetaxel monotherapy in metastatic hormone refractory prostate cancer patients. - PROSTYPatients with metastatic hormone refractory prostate cancerEUCTR2004-004295-37-SEFinnish Uro-Oncological Group360
已完成
2 期
Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate CancerTherapy, Prostatic NeoplasmsNCT00723086Sanofi16